Background: With rising costs of cancer care, this study aims to estimate the prevalence of,
and factors associated with, medical financial hardship intensity and financial sacrifices due …

Oral anticancer medications (OAMs) are high priced with a significant cost-sharing burden to
patients, which can lead to catastrophic financial, psychosocial, and clinical repercussions …

Patients with metastatic or advanced cancer are likely to be particularly susceptible to
financial hardship for reasons related both to the characteristics of metastatic disease and to …

The treatment landscape of advanced prostate cancer (CaP) has evolved significantly over
the past 20 years. As the number of oral anticancer treatment options continues to increase …

Background Bone-modifying agent (BMA) therapy is recommended for metastatic castration-
resistant prostate cancer but not metastatic castration-sensitive prostate cancer (mCSPC) …

PURPOSE: Abiraterone and enzalutamide are commonly used oral cancer therapies for
patients with prostate cancer, both with potentially high out-of-pocket costs for patients. We …

Novel oral targeted drugs are increasingly used for cancer therapy, but their extreme cost,
often exceeding 10,000permonth,posesasignificantbarrierforpatientsandinsur…,leadingtothepotentialbreakdownoftraditiona …

BACKGROUND: Patients with cancer often face financial toxicity. They may face financial
distress because of high out-of-pocket costs that in turn can result in delays in treatment …

Introduction We assessed the proportion of patients with advanced epidermal growth factor
receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive non–small-cell lung cancer …

Background: Each country manages access to anticancer drugs differently due to variations
in the structure and financing of the health system, but a summary of the various strategies …